← Leaderboards
Rachana Singh
Prapela, Inc.
$2,472,247
Attributed
$6,098,023
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,098,023 · 2
By mechanism
U44$3,460,586 · 1
R44$2,637,437 · 1
Top collaborators
- John Phillip Konsin6 shared
- Namasivayam Ambalavanan3 shared
Others in their field
Other Emerging Leaders on “Technology”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$436,612,396
- Valerie Koch · University Corporation For Atmospheric Res$252,793,840
- Joel A Lipkin · Four Points Technology, Llc$178,737,225
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
Research focus
TechnologyHeart RateSafetyClinical ResearchReportingBiomaterial CompatibilityDevicesMedical DeviceInfantVibrotactile StimulationNewborn InfantBreathingInfant CareHospitalsCommercializationCost EffectiveCaringPregnancyPediatricsPrimary OutcomeOutcome MeasureMarketingMasksMattresses
Grant awards (6)
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,475,909
U44 · FY2025 · DA
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$1,484,463
U44 · FY2024 · DA
Prapela® SVS incubator pad: A cost-effective stochastic vibrotactile device to improve the clinical course of infants with apnea of prematurity.$500,214
U44 · FY2023 · DA
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$137,437
R44 · FY2023 · DA
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$1,169,404
R44 · FY2022 · DA
Prapela⢠SVS: A cost-effective stochastic vibrotactile stimulation device toimprove the clinical course of infants with neonatal abstinence syndrome.$1,330,596
R44 · FY2021 · DA